Prostaglandin E2-mediated adenosinergic effects on CD14+cells: Self-amplifying immunosuppression in cancer
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
CD39 and CD73 are surface-expressed ectonucleotidases that hydrolyze ATP in a highly regulated, serial manner into ADP, AMP and adenosine. The end product, adenosine, has both tumor-promoting and immunosuppressive effects. The aim of this study was to determine CD73 expression on immune cells in pleural effusion (PE) in order to have a better understanding of the immune environment in mesothelioma. PE- or blood-derived CD14+ cells of mesothelioma patients and healthy donors were analyzed by flow cytometry for the expression of CD39 and CD73. CD73-induction was studied by exposure of CD14+ cells to the soluble fraction of PE (sPE), while the signaling mechanism, responsible for CD73 induction, by phosphoflow cytometry and receptor-inhibition studies. We observed CD73 expression on CD14+ cells in PE but not peripheral blood of mesothelioma patients or healthy donors. CD73 expression was inducible on CD14+ cells with sPE, cyclic-AMP (cAMP)-inducers (forskolin and prostaglandin-E2 (PGE2)) and adenosine. Inhibition of PGE2 receptors or adenosine A2 receptors blocked CD73-induction by sPE. sPE treatment triggered protein kinase A and p38 activation. However, signal-transducer and activator of transcription 3 (STAT3)-blocking led to enhanced CD73 expression, demonstrating a hitherto unknown negative control of purinergic signaling by STAT3 in CD14+ cells. TNFα production by CD73+ CD14+ cells was significantly impaired in the presence of AMP, confirming immunosuppressive function. Taken together, CD73 expression can be induced by PGE2, cAMP or adenosine on human CD14+ cells. We suggest that targeting this autocrine loop is a valid therapeutic approach in mesothelioma that may also enhance immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Al-Taei et al. showed CD73 expression on TAMs in pleural effusion derived from MPM patients.”
From Chronic Inflammation, Oxidative Stress and Metabolic Plasticity: Three Players Driving the Pro-Tumorigenic Microenvironment in Malignant Mesothelioma (2023) · cites this paper as [132]
The cited source says what the claim attributes to it.
In the citing paper
“This result supports the hypothesis that the TAMs–ADO axis is involved in creating immunosuppressive conditions within the TME of mesothelioma [132].”
From Chronic Inflammation, Oxidative Stress and Metabolic Plasticity: Three Players Driving the Pro-Tumorigenic Microenvironment in Malignant Mesothelioma (2023) · cites this paper as [132]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Deaglio, S., Dwyer, K. M., Gao, W., Friedman, D., Usheva, A., Erat, A., Chen, J.-F., Enjyoji, K., Linden, J., Oukka, M., et al. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20062512 · Cited by 2,470 · cited 1×
“As CD73 enzyme activity results in the generation of adenosine, which induces further CD73 expression on myeloid cells, we describe a self-amplifying loop here which may be similar to the immunosuppressive autocrine adenosinergic loop described for Treg cells.(9) When testing STAT3 activation in CD14C cells exposed to…”
ResultThe function of programmed cell death 1 and its ligands in regulating autoimmunity and infection
Sharpe, A. H., Wherry, E. J., Ahmed, R., & Freeman, G. J. (2007) · Nature Immunology · doi:10.1038/ni1443 · Cited by 1,528
Ohta, A., & Sitkovsky, M. (2001) · Nature · doi:10.1038/414916a · Cited by 1,334 · cited 2×
“Nil PE4 PE5 PE6 PE7 M(4-7) PE8 PE9 C D 73 (m fi)”
BackgroundA2A adenosine receptor protects tumors from antitumor T cells
Ohta, A., Gorelik, E., Prasad, S. J., Ronchese, F., Lukashev, D., Wong, M. K. K., Huang, X., Caldwell, S., Liu, K., Smith, P., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605251103 · Cited by 1,065 · cited 1×
“suppression but also directly supports tumor growth, differentiation, metastasis and angiogenesis.(2,6,7) Cell surface co-expression of CD39 and CD73 ensures rapid”
BackgroundImmunity, inflammation and cancer: a leading role for adenosine
Antonioli, L., Blandizzi, C., Pacher, P., & Haskó, G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3613 · Cited by 765 · cited 1×
“suppression but also directly supports tumor growth, differentiation, metastasis and angiogenesis.(2,6,7) Cell surface co-expression of CD39 and CD73 ensures rapid”
BackgroundSynnestvedt, K., Furuta, G. T., Comerford, K. M., Louis, N. A., Karhausen, J., Eltzschig, H. K., Hansen, K. R., Thompson, L. F., & Colgan, S. P. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15337 · Cited by 679
Increased Level of Extracellular ATP at Tumor Sites: In Vivo Imaging with Plasma Membrane Luciferase
Pellegatti, P., Raffaghello, L., Bianchi, G., Piccardi, F., Pistoia, V., & Di Virgilio, F. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002599 · Cited by 668 · cited 2×
“ATP uptake from the pericellular environment leading to topical generation of adenosine.(1) Double positive cells or extracellular vesicles, such as exosomes,(8) can act as efficient enzyme-”
BackgroundSynnestvedt, K., Furuta, G. T., Comerford, K. M., Louis, N., Karhausen, J., Eltzschig, H. K., Hansen, K. R., Thompson, L. F., & Colgan, S. P. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0215337 · Cited by 660
Extracellular adenosine triphosphate and adenosine in cancer
Stagg, J., & Smyth, M. J. (2010) · Oncogene · doi:10.1038/onc.2010.292 · Cited by 571 · cited 2×
“to have tumor suppressor effects, and, interestingly, P2X7 levels are lower in cancer than in normal tissues.(2) Conversely, the”
BackgroundCancer Exosomes Express CD39 and CD73, Which Suppress T Cells through Adenosine Production
Clayton, A., Al-Taei, S., Webber, J., Mason, M. D., & Tabi, Z. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003884 · Cited by 540
Self-citation
Cited by
Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function
Vigano, S., Alatzoglou, D., Irving, M., Ménétrier-Caux, C., Caux, C., Romero, P., & Coukos, G. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00925 · Cited by 420
Dominant immunosuppression of dendritic cell function by prostate‐cancer‐derived exosomes
Salimu, J., Webber, J., Gurney, M., Al‐Taei, S., Clayton, A., & Tabi, Z. (2017) · Journal of Extracellular Vesicles · doi:10.1080/20013078.2017.1368823 · Cited by 165
“To determine if it was exosomal PGE2 that was inducing the effect, DC were treated with PGE2 receptor antagonists before being cultured with exosomes (Figure 5(b)) at a concentration established previously [19].”
BackgroundMethodSelf-citationFunctional Roles of JNK and p38 MAPK Signaling in Nasopharyngeal Carcinoma
Pua, L. J. W., Mai, C.-W., Chung, F. F.-L., Khoo, A. S.-B., Leong, C.-O., Lim, W.-M., & Hii, L.-W. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031108 · Cited by 164
Eicosanoids in Cancer: New Roles in Immunoregulation
Johnson, A. M., Kleczko, E. K., & Nemenoff, R. A. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.595498 · Cited by 124
“PGE2 has been shown to induce expression of cell-surface ectonucleases CD39 and CD73 on CD14 monocytes (Al-Taei et al., 2017), resulting in production of adenosine is a breakdown product of ATP that mediates tumor progression and immunosuppression.”
BackgroundJennings, M. R., Munn, D. H., & Blazeck, J. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003013 · Cited by 69
Metadata
- Authors
- Al-Taei, S., Salimu, J., Spary, L. K., Clayton, A., Lester, J. F., & Tabi, Z.
- Affiliations
- Division of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, UK
- Cardiff University (GB)
- Velindre NHS Trust (GB)
- Corresponding author
- Tabi, Zsuzsanna
- Venue
- OncoImmunology
- Publisher
- Informa UK Limited
- Published
- 2017-02
- Volume
- 6
- Issue
- 2
- Pages
- e1268308
- ISSN
- 2162-4011 (ISSN-L)
- 2162-402X
- PMC
- PMC5353926
- OpenAlex
- W2560814694
- Cited by
- 17
- References
- 44
- Citations by year
- 2026: 1 · 2024: 1 · 2023: 2 · 2022: 5 · 2021: 2 · 2020: 2 · 2019: 2 · 2018: 1 · 2017: 1
- FWCI
- 1.22
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- OncoImmunology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- ORCA Online Research @Cardiff (Cardiff University) (acceptedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- June Hancock Mesothelioma Research Fund
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Physiology › Adenosine and Purinergic Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Biochemical and Molecular Research
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Keywords
- CD73, CD39, prostaglandin E2, adenosine, CD14+ cells, mesothelioma, pleural effusion, STAT3, protein kinase A, p38 MAPK, purinergic signaling, TNF-α, immunosuppression, cancer immunotherapy, autocrine loop
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prostaglandin E2-mediated adenosinergic effects on CD14+cells: Self-amplifying immunosuppression in cancer. https://app.cochat.ai/papers/10.1080/2162402x.2016.1268308
- The paper
- Al-Taei, S., Salimu, J., Spary, L. K., Clayton, A., Lester, J. F., & Tabi, Z. (2017). Prostaglandin E2-mediated adenosinergic effects on CD14+cells: Self-amplifying immunosuppression in cancer. OncoImmunology. https://doi.org/10.1080/2162402x.2016.1268308
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.